Alterity Therapeutics announced the USPTO granted a new composition of matter patent for its lead clinical asset, ATH434. The patent covers a crystalline form of the mesylate salt and methods for treating neurological conditions, extending protection to at least 2045. This milestone strengthens the intellectual property portfolio as the company prepares to initiate Phase 3 trial activities in Multiple System Atrophy by year-end 2026. The granted patent also enables future development opportunities for ATH434 in Parkinson’s disease and other neurodegenerative disorders involving iron dysregulation and protein aggregation. Alterity Therapeutics is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases.

Alterity Therapeutics received FDA meeting minutes confirming the registrational path for its lead candidate, ATH434. The company operates in the biotechnology industry and develops therapeutic candidates for medical conditions.